Biologics Initiation in Rheumatoid Arthritis by Race and Ethnicity: Results From a Randomized Survey Study

• Published in: ACR open rheumatology Vol. 5; no. 7; pp. 371 - 375
• Main Authors: Simard, Julia F., Lu, Rong, Falasinnu, Titilola O., Baker, Matthew C., Hawa, Saadiya, Deluna, Mariani D., Horomanski, Audra, Fairchild, Robert M.
• Format: Journal Article
• Language: English
• Published: Boston, USA Wiley Periodicals, Inc 01-07-2023; John Wiley & Sons, Inc; Wiley
• Subjects: Ambiguity; Brief Report; Disease; Drug dosages; Ethnicity; Health maintenance organizations; Hispanic Americans; HMOs; Hospitals; Patients; Polls & surveys; Race; Rheumatoid arthritis; Rheumatology; Tumor necrosis factor-TNF; United States > US
• DOI: 10.1002/acr2.11573
• EISSN: 2578-5745

Objective
To investigate whether the race and ethnicity of a patient with rheumatoid arthritis (RA) influences rheumatologists’ likelihood of choosing to initiate biologic disease‐modifying antirheumatic drug (bDMARD) treatment.
Methods
We conducted a randomized survey experiment in which identical brief case vignettes of hypothetical patients with RA were sent to US rheumatologists (respondents). Three of the four cases included some level of treatment decision ambiguity whereas the fourth case strongly favored bDMARD initiation. Each respondent was shown the four case vignettes, with the race and ethnicity (Black, Hispanic, White) randomly assigned for each case. Each vignette offered multiple choices for next therapeutic step, which we summarized using frequencies and proportions by race and ethnicity version.
Results
Among 159 US rheumatologists, we found that for the three cases with some level of treatment decision ambiguity, there was little to no variability in the proportions of respondents who chose to start a biologic for the Black and Hispanic variants (cases 1, 2, and 3). For case 4, respondents generally agreed to start a biologic with some minimal variability across the variants (92.6% for the Black version, 98.1% for the Hispanic version, and 96.2% for the White version).
Conclusion
There are conflicting data regarding bDMARD use and initiation in patients with RA based on the sex and race of the patient. This work adds to this conversation by examining how the next therapeutic step chosen by rheumatologists varied by the race and ethnicity of the hypothetical patient.